» Articles » PMID: 16360345

Effect of Vasopressin on Hemodynamics in Patients with Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction

Overview
Journal Am J Cardiol
Date 2005 Dec 20
PMID 16360345
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

In a retrospective study of 36 patients who developed cardiogenic shock after myocardial infarction, intravenous vasopressin therapy increased mean arterial pressure from 56 to 73 mm Hg at 1 hour (p < 0.001) and maintained it for 24 hours without changing pulmonary capillary wedge pressure, cardiac index, urine output, or other inotropic requirements. After norepinephrine administration, mean pulmonary capillary wedge pressure increased at 1 hour from 21 to 24 mm Hg (p = 0.04); however, this increase was not sustained at 12 and 24 hours. Norepinephrine was associated with a significant increase in cardiac power index at 24 hours, whereas there was only a trend for an increase in cardiac power with vasopressin therapy. In a cohort of patients who developed refractory cardiogenic shock after myocardial infarction, vasopressin was associated with increased mean arterial pressure and no adverse effect on other hemodynamic parameters.

Citing Articles

Higher vasoactive usage despite hemodynamic goals is associated with higher mortality in acute myocardial infarction-related cardiogenic shock.

Ortega-Hernandez J, Gonzalez-Pacheco H, Araiza-Garaygordobil D, Gopar-Nieto R, Sierra-Lara-Martinez D, Manzur-Sandoval D Front Cardiovasc Med. 2025; 12:1461714.

PMID: 40017516 PMC: 11865078. DOI: 10.3389/fcvm.2025.1461714.


Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions.

Jentzer J, Berg D, Chonde M, Dahiya G, Elliott A, Rampersad P JACC Adv. 2024; 4(1):101432.

PMID: 39720581 PMC: 11666941. DOI: 10.1016/j.jacadv.2024.101432.


State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock.

Bloom J, Chan W, Kaye D, Stub D J Am Heart Assoc. 2023; 12(15):e029787.

PMID: 37489740 PMC: 10492962. DOI: 10.1161/JAHA.123.029787.


The medical treatment of cardiogenic shock.

Lescroart M, Pequignot B, Janah D, Levy B J Intensive Med. 2023; 3(2):114-123.

PMID: 37188116 PMC: 10175741. DOI: 10.1016/j.jointm.2022.12.001.


Early Recognition and Risk Stratification in Cardiogenic Shock: Well Begun Is Half Done.

Polyzogopoulou E, Bezati S, Karamasis G, Boultadakis A, Parissis J J Clin Med. 2023; 12(7).

PMID: 37048727 PMC: 10095596. DOI: 10.3390/jcm12072643.